612 related articles for article (PubMed ID: 17896829)
1. Advances in pneumococcal vaccines: what are the advantages for the elderly?
Vila-Córcoles A
Drugs Aging; 2007; 24(10):791-800. PubMed ID: 17896829
[TBL] [Abstract][Full Text] [Related]
2. Vaccinate your child and save its grandparents from a heart attack? Current perspectives in antipneumococcal vaccination.
Vila-Córcoles A
J Intern Med; 2009 Nov; 266(5):432-44. PubMed ID: 19754854
[TBL] [Abstract][Full Text] [Related]
3. Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults.
Durando P; Faust SN; Fletcher M; Krizova P; Torres A; Welte T
Clin Microbiol Infect; 2013 Oct; 19 Suppl 1():1-9. PubMed ID: 24083785
[TBL] [Abstract][Full Text] [Related]
4. The future of pneumococcal disease prevention.
Rodgers GL; Klugman KP
Vaccine; 2011 Sep; 29 Suppl 3():C43-8. PubMed ID: 21896352
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS
Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516
[TBL] [Abstract][Full Text] [Related]
6. Pneumococcal conjugate vaccine for young children.
Selman S; Hayes D; Perin LA; Hayes WS
Manag Care; 2000 Sep; 9(9):49-52, 54, 56-7 passim. PubMed ID: 11116663
[TBL] [Abstract][Full Text] [Related]
7. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
[TBL] [Abstract][Full Text] [Related]
8. Preventing pneumococcal disease in the elderly: recent advances in vaccines and implications for clinical practice.
Vila-Corcoles A; Ochoa-Gondar O
Drugs Aging; 2013 May; 30(5):263-76. PubMed ID: 23420119
[TBL] [Abstract][Full Text] [Related]
9. Pneumococcal vaccination in adults: does it really work?
Pitsiou GG; Kioumis IP
Respir Med; 2011 Dec; 105(12):1776-83. PubMed ID: 21816596
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and safety of the 13-valent Pneumococcal Conjugate vaccine in 23-valent pneumococcal polysaccharide vaccine-naive and pre-immunized patients under treatment with chronic haemodialysis: a longitudinal quasi-experimental phase IV study.
Vandecasteele SJ; De Bacquer D; Caluwe R; Ombelet S; Van Vlem B
Clin Microbiol Infect; 2018 Jan; 24(1):65-71. PubMed ID: 28559003
[TBL] [Abstract][Full Text] [Related]
11. Pneumococcal vaccines.
Ho CF; Lin TY
Chang Gung Med J; 2005 Nov; 28(11):765-72. PubMed ID: 16422182
[TBL] [Abstract][Full Text] [Related]
12. Advances in pneumococcal vaccines: advantages for infants and children.
Bernatoniene J; Finn A
Drugs; 2005; 65(2):229-55. PubMed ID: 15631543
[TBL] [Abstract][Full Text] [Related]
13. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).
Nuorti JP; Whitney CG;
MMWR Recomm Rep; 2010 Dec; 59(RR-11):1-18. PubMed ID: 21150868
[TBL] [Abstract][Full Text] [Related]
14. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine.
Lexau CA; Lynfield R; Danila R; Pilishvili T; Facklam R; Farley MM; Harrison LH; Schaffner W; Reingold A; Bennett NM; Hadler J; Cieslak PR; Whitney CG;
JAMA; 2005 Oct; 294(16):2043-51. PubMed ID: 16249418
[TBL] [Abstract][Full Text] [Related]
15. Pneumococcal vaccines: an update on current strategies.
Bogaert D; Hermans PW; Adrian PV; Rümke HC; de Groot R
Vaccine; 2004 Jun; 22(17-18):2209-20. PubMed ID: 15149779
[TBL] [Abstract][Full Text] [Related]
16. Pneumococcal conjugate vaccine (Prevnar; PNCRM7): a review of its use in the prevention of Streptococcus pneumoniae infection.
Darkes MJ; Plosker GL
Paediatr Drugs; 2002; 4(9):609-30. PubMed ID: 12175274
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) against Pneumococcal Disease in the Elderly: Systematic Review and Meta-Analysis.
Falkenhorst G; Remschmidt C; Harder T; Hummers-Pradier E; Wichmann O; Bogdan C
PLoS One; 2017; 12(1):e0169368. PubMed ID: 28061505
[TBL] [Abstract][Full Text] [Related]
18. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales.
Andrews NJ; Waight PA; George RC; Slack MP; Miller E
Vaccine; 2012 Nov; 30(48):6802-8. PubMed ID: 23000122
[TBL] [Abstract][Full Text] [Related]
19. Use of the 13-valent pneumococcal conjugate vaccine in children and adolescents aged 6 - 17 years.
Mitchell R; Trück J; Pollard AJ
Expert Opin Biol Ther; 2013 Oct; 13(10):1451-65. PubMed ID: 23889554
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
Jackson LA; Gurtman A; Rice K; Pauksens K; Greenberg RN; Jones TR; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
Vaccine; 2013 Aug; 31(35):3585-93. PubMed ID: 23688527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
